{"filings":[{"id":3466757,"accession_number":"0001398733-26-000058","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-10-15T11:21:16+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA accepts Aquestive's Anaphylm NDA resubmission; PDUFA goal date set for March 16, 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA acknowledged the Anaphylm NDA resubmission as complete and classified it as a Class 2 response, setting a PDUFA goal action date of March 16, 2027.","Aquestive resubmitted September 16, 2026 after August 2026 positive topline human factors and PK study data addressed FDA's January 30, 2026 Complete Response Letter.","Anaphylm (dibutepinephrine) sublingual film targets Type I allergic reactions including anaphylaxis; if approved it would be the first oral rescue medication for severe allergic reactions.","Ex-U.S. strategy on track: New Drug Submission to Health Canada planned for Q4 2026.","CEO Daniel Barber said the acceptance gives 'a clear path forward' and that commercial launch preparations are advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3439476,"accession_number":"0001398733-26-000056","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-10-14T11:21:15+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aquestive licenses LIBERVANT seizure-cluster film to Eton for $10M upfront, up to $47.5M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Aquestive received a $10.0M upfront license fee from Eton for exclusive U.S. rights to LIBERVANT (diazepam) buccal film for epilepsy seizure clusters.","Up to $47.5M milestones: $10M at first U.S. commercial sale (cut to $5M absent full FDA approval for ages 2-5), $2.5M for ages 6-11, $35M on net sales.","Aquestive also gets mid-teens royalties on U.S. net sales and serves as exclusive manufacturer under a 20-year supply agreement.","LIBERVANT holds FDA tentative approval; full approval for ages 12+ expected after VALTOCO orphan exclusivity lapses Jan 10, 2027; launch targeted April 2027.","Type 9 NDA to add ages 6-11 has a PDUFA date of March 29, 2027; U.S. seizure rescue market exceeds $450M annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3135356,"accession_number":"0001398733-26-000052","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-09-29T11:22:07+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aquestive Therapeutics elects Richard J. Daly to board, expanding directorships from seven to eight","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard J. Daly elected as Class I director effective October 14, 2026, with term expiring at the 2028 Annual Meeting of Stockholders.","Board size increased from seven to eight directors; seven of eight are independent under Nasdaq listing standards.","Daly receives an initial award of 57,000 stock options under the 2018 Equity Incentive Plan, vesting in annual one-third increments.","Option grant date is the second full trading day after the next quarterly or annual earnings release, with exercise price equal to that day's closing price.","CEO Daniel Barber cited Daly's commercial leadership at AstraZeneca, Takeda and Catalyst as valuable for a potential Anaphylm launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3081876,"accession_number":"0001398733-26-000048","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-09-25T11:59:19+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aquestive furnishes Sept 23, 2026 investor presentation; 8-K text contains no operational or financial detail","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Exhibit 99.1 is titled 'Corporate Presentation' dated September 23, 2026; the appended exhibit text contains only the standard forward-looking-statement disclaimer.","No revenue, EPS, guidance, clinical-trial or partnership data appears anywhere in the filing or the exhibit text provided.","Event date listed as September 23, 2026; the 8-K is dated and signed September 25, 2026 by CFO A. Ernest Toth, Jr.","Company says the deck is available on the Events and Presentations page of the Investors section at www.aquestive.com; content was not reproduced in the filing.","Cannot summarize substantive news because Exhibit 99.1's body was not included beyond the disclaimer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2916716,"accession_number":"0001398733-26-000044","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-09-17T11:02:30+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aquestive resubmits Anaphylm NDA to FDA; addresses CRL with positive human factor/PK data","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resubmitted NDA for Anaphylm (dibutepinephrine) sublingual film to FDA on Sept 17, 2026, for Type I allergic reactions including anaphylaxis.","Human factors study with revised packaging cut median pouch-opening time from 17s to 3s; no protocol-defined use errors in self-administration arm of confirmatory PK study.","Original NDA filed March 2025; FDA CRL issued Jan 30, 2026, requested human factors and confirmatory PK studies.","FDA will determine resubmission classification and set review timeline after initial review of the resubmission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2189525,"accession_number":"0001398733-26-000041","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-08-11T20:06:07+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aquestive Q2 revenue up 38% to $13.8M; Anaphylm NDA resubmission on track for Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $13.8M vs $10.0M; manufacture/supply $11.9M, license/royalty $1.3M.","Net loss $22.9M ($0.18/sh) includes $11.7M one-time debt extinguishment; ex-item net loss $11.2M.","Non-GAAP adjusted EBITDA loss improved to $5.2M from $9.3M; cash $98.5M at June 30.","Anaphylm PK study met primary endpoints; human factors study improved; NDA resubmission on track for Q3 2026.","FY2026 guidance unchanged: revenue $46-50M, adj. EBITDA loss $35-30M; manufacturing 48M doses vs 37M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2144237,"accession_number":"0001398733-26-000035","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-08-10T11:05:44+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aquestive reports positive Anaphylm human factors and PK study results; NDA resubmission on track for Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median pouch-open time cut from 17s to 3s; incorrect film placement down >80% in revised HF study.","PK study: self-admin Cmax 391.7 pg/mL vs clinician 357.6 and IM 334.5; Tmax 12 min vs 45 min for IM.","Top-of-tongue placement still gave Cmax >100 pg/mL and PD comparable to injectable epinephrine.","No serious adverse events or discontinuations in PK study; no administration errors in self-administration arm.","NDA resubmission on track for Q3 2026; also advancing filings in Canada, UK, EU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":972516,"accession_number":"0001398733-26-000033","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-06-10T20:02:32+00:00","items":["5.07","9.01"],"status":"ready","headline":"Aquestive Therapeutics shareholders elect three Class II directors at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gregory B. Brown, M.D. elected with 41,373,033 votes for; 1,222,711 against.","John S. Cochran elected with 36,914,899 votes for; 5,680,845 against.","Abigail L. Jenkins elected with 39,094,166 votes for; 3,501,578 against.","Advisory say-on-pay proposal passed: 37,798,609 for, 3,192,381 against.","KPMG LLP ratified as independent auditor for FY 2026 with 78,804,323 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":67962,"accession_number":"0001398733-26-000029","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-05-13T20:04:40+00:00","items":["1.01","3.02","1.02","2.02","2.03","7.01","9.01"],"status":"ready","headline":"Aquestive Q1 revenue up 66% to $14.4M; secures $150M Oaktree debt facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $14.4M (+66% YoY); license/royalty $5.4M, manufacture/supply $8.8M.","R&D expenses down to $4.2M from $5.4M; SG&A $11.0M vs $19.1M (prior year included $4.3M PDUFA fee).","Reaffirmed Anaphylm NDA resubmission in Q3 2026 after FDA Type A meeting alignment on studies.","Entered $150M Oaktree debt facility: $55M funded, $20M available on FDA approval, $25M on sales milestone.","Used proceeds to repay $45M existing notes; expects $150M cash for Anaphylm launch if approved in 2027."],"consensus_eps_estimate":-0.1399,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":14446000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103591,"accession_number":"0001398733-26-000022","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aquestive completes FDA Type A meeting for Anaphylm; NDA resubmission reaffirmed for Q3 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received FDA clarifying feedback on PK and human factor study designs for Anaphylm.","FDA aligned on labeling to manage potential chewing of film, avoiding additional clinical data.","Container closure changes acknowledged; will be tested in upcoming HF study.","Final FDA meeting minutes expected by early May 2026.","Regulatory submissions for Canada and EU continue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103590,"accession_number":"0001398733-26-000020","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Aquestive Therapeutics appoints new CLO/ CCO; Braender steps down as CLO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lori Braender steps down as CLO and CCO effective April 2, 2026; remains Corporate Secretary.","Thomas Zalewski appointed CLO and CCO effective April 2, 2026; former Partner at Day Pitney.","Zalewski receives inducement grant of 100k RSUs and 75k options, vesting over 3 years.","Braender eligible for severance payments and accelerated vesting under separation agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103589,"accession_number":"0001398733-26-000016","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","9.01"],"status":"ready","headline":"Aquestive posts Q4 net loss of $31.9M; Anaphylm resubmission delayed to Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $13.0M (+10% YoY); net loss $31.9M ($0.26/share) incl $13.6M legal; excl legal net loss $18.7M.","Full year 2025 revenue $44.5M (down 23% YoY); net loss $83.8M ($0.78/share) incl $14.3M legal; cash $121.2M.","FY2026 guidance: revenue $46-50M, Non-GAAP adjusted EBITDA loss $35-30M, year-end cash target $70M.","RTW amendment extends Anaphylm deadline to June 30, 2027; warrant for 375k shares at $4; RTW commits $5M stock purchase.","Anaphylm CRL in Jan 2026; NDA resubmission planned Q3 2026 after Type A FDA meeting within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103588,"accession_number":"0001398733-26-000007","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aquestive Therapeutics files February 2026 investor presentation without new financial data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation furnished under Regulation FD; intended for meetings with institutional investors.","Only a title slide was provided in the exhibit; no specific financial figures or guidance.","No updates to product pipeline, revenue, or strategic initiatives were disclosed.","Ticker AQST continues to trade on Nasdaq; corporate address unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103587,"accession_number":"0001398733-26-000005","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aquestive receives FDA CRL for Anaphylm; deficiencies limited to packaging, administration","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CRL Jan 30, 2026 for Anaphylm NDA; deficiencies in human factors validation study and request for PK study.","Company plans Type A meeting, new HF and PK studies; expects resubmission in Q3 2026.","Global: positive EMA feedback no further trials needed; submit in Europe and Canada H2 2026; UK feedback Q1 2026.","CEO: issues limited to packaging/administration; company well-capitalized to complete approval and pre-launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103586,"accession_number":"0001398733-26-000003","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA identifies deficiencies in Aquestive's Anaphylm NDA, precluding labeling talks","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA letter notes deficiencies in Anaphylm NDA that preclude labeling and post-marketing discussions; review ongoing with PDUFA date Jan 31, 2026.","Company working to understand and resolve deficiencies; delay in potential approval possible if concerns not resolved by PDUFA date.","Unaudited cash and equivalents of ~$120M as of Dec 31, 2025; company believes it is sufficient for U.S. launch and global expansion.","Global strategy advancing: expects to submit in Canada H1 2026, Europe H2 2026, and feedback from UK MHRA in Q1 2026.","Anaphylm supported by 11 clinical studies with ~967 administrations; PK profile comparable to epinephrine auto-injectors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119854,"accession_number":"0001398733-25-000030","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aquestive Therapeutics files Q3 2025 investor presentation; no specific financial details disclosed in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Form 8-K filed on November 6, 2025, under Item 7.01 for Regulation FD disclosure.","Investor presentation attached as Exhibit 99.1, titled 'Q3 Earnings Supplemental Materials'.","Presentation available on company's website, but full content not included in provided filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119853,"accession_number":"0001398733-25-000027","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aquestive Q3 net loss $15.4M; Anaphylm PDUFA Jan 31, 2026, launch prep ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $12.8M (+4% YoY excluding one-time 2024 deferred revenue); net loss $15.4M ($0.14/sh) vs $11.5M loss in Q3 2024.","Cash $129.1M; full-year 2025 revenue guidance $44-50M, non-GAAP adjusted EBITDA loss $47-51M.","Anaphylm NDA on track for Jan 31, 2026 PDUFA; FDA will not hold AdCom; US launch planned Q1 2026 if approved.","Two new Anaphylm patents issued Oct 2025 extending protection to 2037; IND for AQST-108 topical epinephrine gel for alopecia areata on track for Q4 2025.","Added clinical leadership for AdrenaVerse pipeline; supply chain largely unaffected by tariffs."],"consensus_eps_estimate":-0.1352,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":31530000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119852,"accession_number":"0001398733-25-000022","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aquestive receives two new US patents for Anaphylm, extending protection to 2037","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO issued U.S. patent nos. 12,427,121 and 12,443,850 covering epinephrine prodrug compositions for sublingual film delivery.","Patents expire May 4, 2037, subject to extensions; protect proprietary composition enabling oral film delivery.","Anaphylm (dibutepinephrine) sublingual film, if FDA approved, would be first oral rescue treatment for severe allergic reactions.","PDUFA target action date for Anaphylm is January 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119851,"accession_number":"0001398733-25-000020","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aquestive Therapeutics furnishes October 2025 investor presentation","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation includes company overview, pipeline, and strategy; no new financial results disclosed.","Filed under Regulation FD as a routine investor presentation for institutional meetings.","No specific material changes or guidance updates noted in the exhibit text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136418,"accession_number":"0001398733-25-000018","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aquestive presents at H.C. Wainwright conference; no material updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation furnished as Exhibit 99.1; only cover slide text included in filing.","No financial results, pipeline data, or guidance changes provided in the 8-K.","Filing is a routine Regulation FD disclosure for a conference presentation.","No specific numbers, names, or events beyond the presentation's existence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136417,"accession_number":"0001398733-25-000016","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA will not require advisory committee for Aquestive's Anaphylm NDA; PDUFA Jan 31, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA informed Aquestive that no advisory committee meeting is required for Anaphylm (dibutepinephrine) Sublingual Film NDA.","PDUFA target action date remains January 31, 2026; commercial planning underway for rapid post-approval launch.","Anaphylm could be first FDA-approved, non-invasive, orally delivered epinephrine for severe allergic reactions, including anaphylaxis.","Company recently completed $160M in financing activities to support broad healthcare provider and patient outreach upon approval.","NDA includes 11 clinical studies with 967 administrations (single and repeat dose) in adults and children over 30 kg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136416,"accession_number":"0001140361-25-031374","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Aquestive prices $85M common stock offering of 21.25M shares at $4.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offers 21.25M shares at $4.00/share; expected gross proceeds $85M, closing Aug 15, 2025.","Proceeds to primarily fund launch/commercialization of Anaphylm (epinephrine sublingual film) pending FDA approval.","Offering led by RTW Investments; includes Samsara BioCapital, EcoR1 Capital, Perceptive Advisors, others.","Joint bookrunning managers: Leerink Partners, Cantor, Oppenheimer; H.C. Wainwright lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136415,"accession_number":"0001140361-25-031008","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Aquestive secures $75M funding from RTW for Anaphylm launch, contingent on FDA approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$75M purchase price from RTW, subject to FDA approval of Anaphylm and refinancing of existing 13.5% senior notes.","Revenue share payments of 7.5%-1.0% of US net sales (9.5% if low sales) capped at $187.5M by 2035 or $225M thereafter.","Funding supports commercial launch; CEO says capital through 2027; Cantor Fitzgerald advised Aquestive.","RTW Managing Partner Roderick Wong: 'investment reflects belief in Anaphylm's commercial prospects.'"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136414,"accession_number":"0001398733-25-000012","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aquestive Q2 net loss $13.5M; FDA accepts Anaphylm NDA, PDUFA Jan 31, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $10.0M, down 50% YoY; excluding one-time deferred revenue, up 3% to $10.0M.","Net loss $13.5M ($0.14/sh) vs $2.7M loss ($0.03) in Q2 2024; adjusted EBITDA loss $9.3M.","Cash $60.5M at June 30; FY2025 guidance: revenue $44-50M, adjusted EBITDA loss $47-51M.","FDA accepted Anaphylm NDA; PDUFA date Jan 31, 2026; Q1 2026 launch planned if approved.","Anaphylm global expansion to Canada and EU; AQST-108 IND for alopecia areata expected Q4 2025."],"consensus_eps_estimate":-0.1717,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":18723000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136413,"accession_number":"0001628280-25-034890","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aquestive obtains Health Canada meeting for Anaphylm NDS; EMA briefing book submitted","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Health Canada grants Q3 2025 meeting for planned New Drug Submission of Anaphylm (epinephrine) Sublingual Film.","Initial briefing book submitted to European Medicines Agency; MA submission planned as soon as possible.","U.S. NDA accepted with PDUFA target action date of January 31, 2026.","Company pursuing parallel ex-U.S. regulatory pathways for needle-free, device-free anaphylaxis treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153562,"accession_number":"0001628280-25-031455","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA accepts Aquestive's NDA for Anaphylm; PDUFA date Jan 31, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA for Anaphylm (epinephrine oral film) to treat Type 1 allergic reactions, including anaphylaxis.","PDUFA target action date assigned as January 31, 2026; FDA may hold an Advisory Committee meeting.","If approved, Anaphylm would be first and only orally delivered epinephrine option in the U.S.","Product is a thin, device-free film that requires no special storage, fitting in wallet or pocket."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153561,"accession_number":"0001628280-25-030804","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aquestive shareholders elect two Class I directors, approve say-on-pay, ratify KPMG at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Daniel Barber and Timothy E. Morris elected as Class I directors with 36,060,882 and 35,562,599 votes for, respectively.","Non-binding advisory vote on executive compensation approved: 32,454,278 for, 6,694,084 against, 459,188 abstain.","Ratification of KPMG as independent auditor for FY 2025 passed: 66,530,646 for, 1,166,766 against.","Broker non-votes of 29,848,112 on director elections and say-on-pay proposal.","Annual Meeting held June 11, 2025; results reported under Item 5.07."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153560,"accession_number":"0001628280-25-028813","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aquestive furnishes June 2025 corporate presentation; no specific new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation dated June 2025 provided for institutional meetings.","No financial or operational updates (e.g., revenue, pipeline) are evident from the excerpt.","Presentation available on company's investors website.","Filing is a routine Reg FD disclosure, not a material event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153559,"accession_number":"0001628280-25-024659","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aquestive Q1 net loss $22.9M; cuts FY revenue guidance on Libervant setback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $8.7M, down 28% YoY from $12.1M; net loss $0.24/share vs $0.17 loss last year.","NDA for Anaphylm submitted; plans Q1 2026 launch if FDA approved; will not appeal Libervant court decision.","Libervant reclassified to tentative approval; sales/marketing paused; FY revenue guidance cut to $44-50M.","Non-GAAP adjusted EBITDA loss $17.6M vs $7.2M prior year; cash $68.7M.","De-emphasizing AQST-108 (alopecia) until after Anaphylm launch to focus resources."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":8720000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153558,"accession_number":"0001628280-25-015759","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aquestive reports positive pediatric PK results for Anaphylm; NDA submitted to FDA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Pediatric study (32 patients aged 7-17, >30 kg) shows PK consistent with adult studies; no serious adverse events.","Anaphylm NDA submitted to FDA; acceptance decision expected in Q2 2025.","Company targets Q1 2026 launch if FDA approves Anaphylm.","Positive pediatric data could enable a label covering patients aged 7 and older."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172284,"accession_number":"0001628280-25-011465","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aquestive Therapeutics files March 2025 investor presentation; no material new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a corporate presentation for meetings with institutional investors and analysts.","Presentation covers corporate overview, pipeline, and portfolio strategy.","No specific financial guidance, product updates, or business milestones were included in the filing text.","Presentation available on company's website; not deemed filed under Exchange Act.","Confidence low due to absence of substantive new information in the excerpt provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172283,"accession_number":"0001628280-25-010422","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aquestive starts Anaphylm NDA filing; Q4 net loss $17.1M; 2025 revenue guidance $47-56M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 total revenues $11.9M, down 10% YoY; full-year revenues $57.6M, up 14%.","Q4 net loss $17.1M ($0.19/sh) vs $8.1M loss ($0.12/sh) YoY; FY net loss $44.1M ($0.51/sh) vs $7.9M ($0.13/sh).","Anaphylm NDA submission started, FDA acceptance expected Q2 2025; launch targeted Q1 2026 if approved.","AQST-108 Phase 2a in alopecia areata to begin Q2 2025; Libervant court ruling appealed, product remains on market.","Pro-forma cash ~$93M including $21.4M ATM proceeds in Feb 2025; 2025 revenue guidance $47-56M, Non-GAAP EBITDA loss $46-53M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172282,"accession_number":"0001628280-25-005018","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aquestive to present Anaphylm data at AAAAI: symptom resolution in 12 min, stable under extreme conditions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median symptom resolution time 12 min vs 74 min without treatment; mean angioedema resolution within 5 min.","Anaphylm matched or exceeded IM epinephrine in all key PK parameters in Phase 2 OASIS study.","Stability and potency maintained under extreme heat, freezing, and water submersion.","Presentations at AAAAI Annual Meeting Feb 28 – Mar 3, 2025 in San Diego."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172281,"accession_number":"0001628280-25-001229","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aquestive provides business update; on track to submit Anaphylm NDA in Q1 2025; cash ~$70M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On track to submit Anaphylm (epinephrine) Sublingual Film NDA to FDA in Q1 2025; potential approval/launch as early as Q1 2026.","Successfully completed pre-IND meeting for AQST-108 (epinephrine) Topical Gel; Phase 2a in alopecia areata to begin Q2 2025.","Unaudited cash and cash equivalents approximately $70 million as of Dec 31, 2024.","Libervant (diazepam) Buccal Film received FDA approval for ages 2-5 and Orphan Drug Exclusivity until April 2031.","CEO outlines 2025 focus: Anaphylm launch prep, ex-U.S. strategy, AQST-108 Phase 2a, Libervant expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189279,"accession_number":"0001628280-24-051956","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Aquestive 7-year orphan drug exclusivity for Libervant in pediatric seizure clusters ages 2-5","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted 7 years of orphan drug exclusivity to Libervant (diazepam) Buccal Film for treating seizure clusters in patients aged 2-5.","Exclusivity extends to April 2031; FDA cited buccal route as major contribution to patient care vs rectal route.","Libervant is the first and only FDA-approved orally administered rescue therapy for this pediatric population.","Originally designated as orphan drug in 2016; ODE now granted following approval on April 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189278,"accession_number":"0001628280-24-049497","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aquestive receives positive FDA feedback for Anaphylm; reaffirms Q1 2025 NDA submission","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed on NDA content, safety evaluation, and pediatric trial plan; no additional adult trials needed.","Single-dose pediatric trial commenced in U.S. and Canada in December 2024.","FDA noted an advisory committee meeting may be necessary due to new route of administration.","Reaffirms NDA submission guidance for Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189277,"accession_number":"0001628280-24-046223","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aquestive board member Santo J. Costa resigns; Cochran and Morris assume committee roles","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Santo J. Costa resigned from board effective Nov 4, 2024 for personal reasons; no disagreement with company.","John S. Cochran appointed Chair of Compensation Committee effective Nov 4, 2024.","Timothy E. Morris added to Compensation Committee; board size reduced from 8 to 7 directors.","Company thanked Costa for his years of service and dedication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189276,"accession_number":"0001628280-24-045687","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aquestive Therapeutics files investor presentation for November 2024 with no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Furnished an investor presentation dated November 2024 under Item 7.01 Regulation FD.","Presentation includes corporate overview; no specific financial or operational updates provided.","No new guidance, product announcements, or changes in strategy disclosed in the exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189275,"accession_number":"0001628280-24-045028","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aquestive Q3 net loss $11.5M vs $2.0M; revenue up 4% to $13.5M; Anaphylm pre-NDA meeting in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $13.5M (+4% YoY); net loss $11.5M ($0.13/sh) vs $2.0M loss in Q3 2023.","Cash $77.9M; FY2024 guidance: revenue $57-60M, adj EBITDA loss $20-23M.","Anaphylm pre-NDA meeting with FDA scheduled Q4 2024; NDA submission targeted Q1 2025, launch Q1 2026 if approved.","AQST-108 (epinephrine topical gel) pre-IND meeting Q4 2024; Phase 2a in alopecia areata planned Q2 2025.","Libervant launched for ages 2-5 with dedicated sales force; commercial and Medicaid coverage expanded nationwide."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":45694000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189274,"accession_number":"0001628280-24-043761","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aquestive presents Anaphylm data showing consistent PK/PD regardless of film movement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["87.5% of subjects had no film movement; 12.5% showed movement with no significant PK/PD impact.","Geometric mean Cmax: 351.14 pg/mL (movement) vs 490.27 pg/mL (no movement); p=0.49.","Median Tmax was 12 minutes for both groups; comparable to epinephrine injection.","Data supports Anaphylm as a potential needle-free epinephrine option for anaphylaxis if FDA-approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189273,"accession_number":"0001628280-24-043505","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aquestive positive OAS study: Anaphylm resolves symptoms in 12 min median, meets endpoints","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OAS challenge study met primary and secondary endpoints; no significant PK difference with vs. without allergen.","Median time to complete symptom resolution: 12 minutes (vs. 74 minutes at screening); symptoms began resolving as early as 2 min.","All instances of symptomatic swelling resolved within 5 minutes after Anaphylm administration.","Pre-NDA meeting with FDA requested in Q4 2024; NDA submission planned Q1 2025; potential launch Q1 2026 if approved.","Anaphylm is a non-invasive oral epinephrine film for severe allergic reactions; adverse events mild/moderate and resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189272,"accession_number":"0001628280-24-042948","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Aquestive amends bylaws: shortens nomination look-back to 2 years, updates terminology","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholder nomination look-back period shortened from three years to two years.","All references to 'chairman' replaced with 'chair' for modernization.","Amendments approved by Board and effective immediately on October 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205772,"accession_number":"0001628280-24-041432","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aquestive completes Anaphylm oral allergen challenge enrollment; unveils AQST-108 Phase 2 for alopecia areata","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anaphylm (epinephrine sublingual film) oral allergen challenge study fully enrolled; topline data expected Q4 2024.","Pre-NDA meeting request submitted to FDA; NDA submission planned for Q1 2025, launch by end-2025 or early 2026.","AQST-108 (epinephrine topical gel) first human study completed: no serious adverse events, zero plasma drug levels observed.","AQST-108 to be developed for alopecia areata (6.7M US patients); Phase 2 design outlined for mild-to-moderate disease.","Pre-IND meeting for AQST-108 targeted Q1 2025; Phase 2 initiation expected H2 2025 pending FDA alignment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205771,"accession_number":"0001628280-24-039783","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aquestive Therapeutics furnishes investor presentations; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed Form 8-K on September 9, 2024 to disclose investor presentation and H.C. Wainwright conference slides.","Presentations provided as Exhibit 99.1 and 99.2; no specific financial updates or guidance changes were included in the filing.","Information is furnished under Regulation FD and not deemed filed for SEC liability purposes.","No material new business developments, earnings data, or strategic actions were reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205770,"accession_number":"0001628280-24-037053","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aquestive reiterates Q1 2025 NDA filing for Anaphylm; notes FDA approval of non-injection epinephrine","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Daniel Barber applauds FDA approval of first non-injection-based epinephrine device for anaphylaxis.","Reiterates NDA submission for Anaphylm (epinephrine) Sublingual Film in Q1 2025.","Oral allergy syndrome (OAS) challenge study completion expected late Q3 or early Q4 2024.","Full product launch of Anaphylm, if approved, targeted for end of 2025 or Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205769,"accession_number":"0001628280-24-035223","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aquestive Q2 revenue up 52% to $20.1M; narrows net loss; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $20.1M vs $13.2M YoY; net loss $2.7M ($0.03/sh) improves from $5.8M loss.","Non-GAAP adjusted EBITDA positive $1.8M vs -$3.3M; cash $89.9M.","Raises FY24 revenue guidance to $57-60M (prev. $48-51M); adj. EBITDA loss guidance narrowed to $20-23M.","Anaphylm NDA submission on track for Q1 2025; launch expected end 2025/early 2026.","Libervant expanded to ages 2-5; national retail distribution expected Q4 2024; epinephrine prodrug investor day planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":32152000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205768,"accession_number":"0001628280-24-032917","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aquestive reports positive topline PK data for Anaphylm self-administration study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Self-administration PK study met primary endpoints; PK comparable whether administered by subjects or HCPs.","Median Tmax of 15 minutes for Anaphylm self-admin & HCP-admin vs 50 minutes for Adrenalin IM injection in 36 healthy adults.","Remaining supportive OAS challenge study underway, expected completion late Q3 or early Q4 2024.","Company maintains NDA filing guidance late Q4 2024/early Q1 2025 and product launch by end 2025 or Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222730,"accession_number":"0001628280-24-029340","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aquestive Therapeutics reports 2024 annual meeting voting results","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Santo J. Costa, Julie Krop, and Marco Taglietti as Class III directors with 24.9M, 21.6M, and 24.9M votes for.","Non-binding advisory vote on executive compensation approved: 23.6M for, 1.6M against.","Advisory vote frequency set at one year (24.6M for).","Ratified KPMG as independent auditor for FY 2024: 50.7M for, 0.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.04,"calibrated_materiality_score":0.04,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222729,"accession_number":"0001628280-24-027167","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aquestive Therapeutics furnishes investor presentation; no specific material updates provided in filing text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed Form 8-K on June 6, 2024, to disclose an investor presentation to institutions and analysts.","Presentation dated June 6, 2024, is attached as Exhibit 99.1 and posted on company website.","No financial results, guidance, or operational changes are explicitly stated in the filing.","Presentation covers 'Advancing medicines. Solving problems. Improving lives.' tagline only.","Filing is a routine FD disclosure; materiality cannot be determined without full presentation content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222728,"accession_number":"0001628280-24-027028","cik":1398733,"company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aquestive Therapeutics promotes Cassie Jung to COO effective June 3, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cassie Jung, 45, promoted to Chief Operating Officer, effective June 3, 2024.","Jung joined Aquestive in 2004 and served as VP Operations since 2019.","Annual base salary increased to $349,800; target incentive at least 40% of base.","No family relationships with directors/officers or reportable transactions.","Employment agreement will be filed with next 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":504936728.975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-06-06T23:59:59+00:00|222728"}